Monte Rosa Therapeutics, Inc.

NASDAQ:GLUE

7.14 (USD) • At close December 23, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

20232022202120202019
Revenue 00000
Cost of Revenue 6.2228.5592.1320.5370.072
Gross Profit -6.222-8.559-2.132-0.537-0.072
Gross Profit Ratio 00000
Reseach & Development Expenses 111.27285.06157.15524.0057.35
General & Administrative Expenses 32.03927.32315.7274.0050.644
Selling & Marketing Expenses 00000
SG&A 32.03927.32315.7274.0050.644
Other Expenses 00-0.96-7.680.276
Operating Expenses 143.311112.38472.88228.017.994
Operating Income -143.311-112.384-72.882-28.01-7.994
Operating Income Ratio 00000
Total Other Income Expenses Net 8.2973.883-1.076-7.8690.254
Income Before Tax -135.014-108.501-73.958-35.879-7.74
Income Before Tax Ratio 00000
Income Tax Expense 0.338-3.883-2.0160.1890.277
Net Income -135.352-104.618-71.942-36.068-8.017
Net Income Ratio 00000
EPS -2.63-2.22-1.55-0.82-0.18
EPS Diluted -2.63-2.22-1.55-0.82-0.18
EBITDA -137.089-99.942-70.75-27.473-7.667
EBITDA Ratio 00000